Use of eltrombopag in a pediatric patient with primary immune thrombocytopenia

Carlos Chávez-Trillo; MS Enríquez-Ramos

2017, Number 1

<< Back Next >>

Rev Hematol Mex 2017; 18 (1)

Use of eltrombopag in a pediatric patient with primary immune thrombocytopenia

Chávez-Trillo C, Enríquez-Ramos MS

Full text

How to cite this article

Language: Spanish
References: 0
Page: 36-40
PDF size: 90.35 Kb.

ABSTRACT

The primary immune thrombocytopenia (PIT) is an acquired autoimmune disorder that results in the destruction of platelets mediated by antibodies. Pediatric patients are usually characterized by having a benign evolution, with a spontaneous remission. However, some patients will evolve to a chronic form, which may be refractory to the first lines of treatment, whereby recently was approved the use of new thrombopoietic agents, such as romiplostim and eltrombopag, an alternative treatment for the chronic primary immune thrombocytopenia (CPIT) in children. In this investigation it is reported the case of an 8-year patient with CPIT and his evolution using eltrombopag, which seems to be a safe and well tolerated treatment due to an increase of the number of platelets in function of the dose.